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Treatment for non-metastatic breast cancer (BC) may be the cause of second malignancies in long-term survivors. Our aim was to
investigate whether survivors present a higher risk of malignancy than the general population according to treatment received. We
analysed data for 16705 BC survivors treated at the Curie Institute (1981–1997) by either chemotherapy (various regimens),
radiotherapy (high-energy photons from a
60Co unit or linear accelerator) and/or hormone therapy (2–5 years of tamoxifen). We
calculated age-standardized incidence ratios (SIRs) for each malignancy, using data for the general French population from five
regional registries. At a median follow-up 10.5 years, 709 patients had developed a second malignancy. The greatest increases in risk
were for leukaemia (SIR: 2.07 (1.52–2.75)), ovarian cancer (SIR: 1.6 (1.27–2.04)) and gynaecological (cervical/endometrial) cancer
(SIR: 1.6 (1.34–1.89); Po0.0001). The SIR for gastrointestinal cancer, the most common malignancy, was 0.82 (0.70–0.95;
Po0.007). The increase in leukaemia was most strongly related to chemotherapy and that in gynaecological cancers to hormone
therapy. Radiotherapy alone also had a significant, although lesser, effect on leukaemia and gynaecological cancer incidence. The
increased risk of sarcomas and lung cancer was attributed to radiotherapy. No increased risk was observed for malignant melanoma,
lymphoma, genitourinary, thyroid or head and neck cancer. There is a significantly increased risk of several kinds of second malignancy
in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some cases.
However, the absolute risk is small.
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The overall survival rate of patients with early advanced breast
cancer (BC) has increased over the years largely because adjuvant
therapy, whether chemotherapy, radiotherapy or hormone
therapy, has helped prevent local and distant failures (Fox, 1979;
Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies
that occur in long-term survivors may be due to sporadic cancers
that would have occurred anyway, environmental or genetic
factors (Klijn et al, 1997; Schrag et al, 1997; Turner et al, 1999;
Meijers-Heijboer et al, 2000; Pierce et al, 2000, 2003; Stoppa-
Lyonnet et al, 2000; Galper et al, 2002; Kauff et al, 2002; Pierce,
2002; Robson, 2002; Seynaeve et al, 2004; Kirova et al, 2005a,b,
2006a; Laki et al, 2007), or BC treatment (Neugut et al, 1993; Inskip
et al, 1994; Ahsan and Neugut, 1998; Karlsson et al, 1998; Kirova
et al, 1998, 2005a,b, 2007; Obedian et al, 2000; Rubino et al, 2000;
Scholl et al, 2001; Shousha et al 2001; Yap et al, 2002, 2005;
Deutsch et al, 2003; Zablotska and Neugut, 2003; Zablotska et al,
2005; Mellemkjaer et al, 2006)
The aim of this study was to estimate the risk of a second
malignancy after adjuvant treatment for BC in a homogeneous
cohort of patients from a single institution. The observed
incidence of second malignancies in these BC patients was
compared with the expected age-adjusted number of new cases
in the general population of French women as given by data from
five regional registries (Remontet et al, 2003).
PATIENTS AND METHODS
We analysed data for 16705 consecutive patients with non-
metastatic BC who were treated at the Institut Curie between 1981
and 1997. The data, including treatments, were entered prospec-
tively into the Institute’s BC database set up in 1981 (Salmon et al,
1997). Chemotherapy regimens in adjuvant and neoadjuvant
setting varied over time based on CMF (cyclophosphamide,
methotrexate and 5-fluorouracile), FAC (5-fluorouracile, adriamy-
cine and cyclophosphamide) or FEC (epirubicin). All patients
received alkylating agents and the majority received anthracyclins.
Hormonal therapy consisted mostly of 2–5 years of administration
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sof tamoxifen. Patients who underwent radiotherapy received high-
energy photons produced by a
60Co unit or linear accelerator, as
previously described, either as sole treatment or pre- or post
surgery (Fourquet et al, 1991; Campana et al, 2005; Kirova et al,
2006b). Follow-up included a six-monthly clinical examination and
a once-yearly mammogram for 5 years, and then a once-yearly
clinical examination and a unilateral or bilateral mammogram for
the lifetime of every patient. All follow-up data were entered into
the database. At 5 years, 5% of patients were lost to follow-up and
at 10 years, 8% were lost to follow-up.
We recorded clinical and primary tumour variables, radiation
history and irradiation fields, for all patients with histologically
confirmed second malignancies. Second malignancies included all
first cancers occurring after treatment of the primary BC, but
excluded contralateral BC.
Statistical analysis
We first calculated Kaplan–Meier cumulative incidence and the
10-year risk of developing each type of second malignancy (Kaplan
and Meier, 1958). The observed crude incidence rates in the entire
patient population (cases per 100000 person-years) were then
compared with the expected incidence in the general population of
French women as given by age-standardized data from five
regional registries (Remontet et al, 2003), and a standardized
incidence ratio (SIR) was calculated for each malignancy. We then
calculated the SIRs for the highest-risk malignancies according to
the adjuvant treatment the patients had received to study the
impact of treatment on risk. The Poisson regression model was
used to adjust the analysis. The data were analysed using ‘S Plus
6.2, Insightful Corp.’ software.
RESULTS
Median follow-up was 10.5 years (range 0.2–24 years). Median
patient age at the time of BC diagnosis was 56.2 years. Of the total
population of 16705 patients, 13472 (80.6%) received radiation
therapy, 2347 (17.4%) underwent mastectomy followed by radio-
therapy, 8596 (63.8%) lumpectomy then radiotherapy, and 2529
(18.8%) were treated by radiotherapy alone. A total of 4528
patients (27.1%) received chemotherapy (14.3% chemotherapy
alone; 12.8% chemotherapy plus hormone therapy) and 16.5%
received hormone therapy alone. Overall, 9414 patients (56.4%)
did not receive any systemic adjuvant therapy. The number of
patients receiving different treatment combinations is given in
Table 1.
By 10.5 years of median follow-up, 709 patients had developed a
second malignancy. Table 2 gives the cumulative incidence of
second malignancies 10.5 years after BC in the study population by
decreasing order of incidence. Gastrointestinal (GI) cancer was the
most common cancer, followed by gynaecological cancer (cervical
and endometrial) and ovarian cancer. Table 3 compares the
observed crude incidence in patients and the incidence in the
general population of French women. Of all the malignancies, only
leukaemia, ovarian and other gynaecological cancers (cervical and
endometrial), and GI tumours, showed a significantly higher
incidence in patients than in the general population. Among the 74
patients with histologically confirmed primary ovarian cancer, 13
underwent genetic testing because they presented a familial history
of BC or ovarian cancer and, of these 13 patients, 10 were carriers
of BRCA mutations (9 of BRCA1,1o fBRCA2).
The extent to which the different treatments constituted risk
factors for a second malignancy is shown in Table 4. Chemo-
therapy was the most important risk factor for leukaemia and
highly significantly increased the risk of this disease. Radiotherapy
was a much less significant risk factor. Both hormone treatment
and radiotherapy were significant risk factors for gynaecological
cancers. The SIR of ovarian cancer was threefold higher in patients
who had received radiotherapy plus chemotherapy than in patients
receiving no adjuvant therapy. The combination treatment was a
highly significant risk factor. Chemotherapy alone had no
significant effect maybe because of the small number of events
and lack of statistical power. We found no relationship between GI
tumours and BC treatment (not shown).
DISCUSSION
To our knowledge, this is the largest retrospective study from a
single institution on second malignancies and one of the first to
attempt to relate the incidence and risk of a second malignancy in
patients with non-metastatic BC to the expected number of cases in
the general population of women of the same age, after stratifying
patients by treatment received (Rubino et al, 2000). Patients
treated for BC showed increased risk of leukaemia, ovarian cancer,
and gynaecological cancers, and a slightly enhanced risk of GI
cancers, in addition to the well-known risk of developing sarcomas
(Kirova et al, 2005b) and lung cancer after radiation therapy
(Kirova et al, 2007). The increase in leukaemia was most strongly
related to chemotherapy (alkylating agents) and that in gynaeco-
logical cancers to hormone therapy (the main treatment was
tamoxifen). Radiation therapy alone also had a significant, but
lesser, effect found only in comparison with the general population
(Rubino et al, 2000).
There was no difference between irradiated and non-irradiated
patients with regard to leukaemia risk (Kirova et al, 2007), but
there was a significant difference between our patients and the
general population. Such a difference has already been noted and
has been related to the use of adjuvant chemotherapy (7, 13, 19, 34;
Rubino et al, 2000). At the Institut Gustave Roussy, the overall SIR
for leukaemia was 3.1 (95% confidence interval (CI): 1.7–5.0) in
Table 1 Distribution of patients by treatment
Number of patients (%)
Systemic treatment No radiotherapy Radiotherapy Total
None 2371 7043 9414 (56.4)
Chemotherapy (CT) 169 2221 2390 (14.3)
Hormone therapy (HT) 509 2254 2763 (12.8)
CT and HT 185 1953 2138 (16.5)
Total 3234 (19.4) 13472 (80.6) 16705 (100)
Table 2 Ten-year cumulative incidence of second malignancy (Kaplan–
Meier estimates)
n (%) 95% CI
Gastrointestinal 182 11.5 9.5–13.4
Gynaecological
a 132 8.6 6.9–10.2
Ovary 74 5.0 3.8–6.3
Lung 58 3.7 2.6–4.9
Leukaemia 47 3.3 2.3–4.3
Melanoma 37 2.8 1.8–3.8
Lymphoma 41 2.6 1.7–3.5
Genitourinary 41 2.2 1.4–3.0
Sarcoma 34 2.1 1.3–3.0
Others 25 1.6 0.8–2.3
Thyroid 20 1.4 0.7–2.1
Head and neck 18 1.1 0.5–1.6
Total 709 45.0 41.2–48.7
Abbreviation: CI¼confidence interval.
aCervical and endometrial.
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s4416 BC patients and 2.1 (95% CI: 1.1–3.5) in the subpopulation of
416 patients receiving chemotherapy (Rubino et al, 2000).
Our observation of an increased risk of ovarian cancer confirms
previous findings (Easton et al, 1993; Breast Cancer Linkage
Consortium, 1997; Fisher et al, 1998; Chappuis et al, 2000; Haber,
2002; Haffty et al, 2002; Kauff et al, 2002; Pierce et al, 2003; Blamey
et al, 2004) and suggests that these patients may have a familial
predisposition to BC and ovarian cancer. Although we tested 13 of
74 patients with ovarian cancer for BRCA1 or BRCA2 mutations
and found a mutation in 10 of the 13 patients with familial cancer,
this result is not representative of the whole population of patients.
We included patients as from 1981, but only began genetic testing
in the early nineties. The increased risk of endometrial cancer
might be due to tamoxifen use, as shown by others (Ewertz and
Mouridsen, 1985; Brenner et al, 1993; Volk and Pompe-Kirn,
1997). Confirmation of this would need distinguishing different
types of hormone therapy (anti-estrogens, anti-aromatase) from
surgical hysterectomy and radiation-induced castration.
No relationship between GI cancers and different treatment
modalities was observed. This and our previous study did not find
increased incidence of oesophageal cancers, related to the
radiation treatment (Kirova et al, 2007).
A major strength of our study is the large volume of individual
patient data from a single institution. This differentiates it from
epidemiological studies that lack individual data on patient
treatment and from most single-institution series that are much
smaller. However, despite the large number of patients and long
follow-up (10.5 years), the incidence of second malignancies may
nevertheless remain underestimated because of the long latency
period of some tumours.
In conclusion, this study has confirmed an increased risk of
second malignancies in women treated for BC, compared with the
general population. This increase may be related to adjuvant
treatment in some cases. However, the absolute risk is small and
the influence of other predisposing factors, such as for instance
family history of cancer and history of smoking, will need to be
investigated in a prospective study, preferably with a long enough
follow-up to exclude other late complications.
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